Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Summary

This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human papillomavirus (HPV18+) cervical infection. The DNA vaccine is designed to promote an immune response to treat disease caused by HPV types 16 and 18, viruses that can cause cervical cancer. The pBI-11 DNA vaccine or a placebo will be administered intramuscularly using the TriGridTM Delivery System.

Timeline

Start

2026-06-25

Primary completion

2028-11

Completion

2029-05

Drugs

Indications